Topics:

N E W P R O D U C T

N E W P R O D U C T

PALO ALTO, Calif--ALZA Corporation and U.S. Bioscience, Inc. have announced the availability of Ethyol (amifostine), which was FDA approved in December, 1995.

The agent is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin (Platinol) in patients with advanced ovarian cancer or non-small-cell lung cancer. In these settings, the clinical data do not suggest that the effectiveness of cisplatin-based chemotherapy regimens is altered by use of Ethyol.

There are at present only limited data on the influence of Ethyol on the efficacy of chemotherapy in other settings; therefore, Ethyol should not be given to patients in other settings where chemotherapy can produce a significant survival benefit or cure (eg, certain malignancies of germ cell origin), except in the context of a clinical study.

ALZA will be responsible for US sales and marketing of Ethyol.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.